Integrated safety in tocilizumab clinical trials by Schiff, Michael H et al.
RESEARCH ARTICLE Open Access
Integrated safety in tocilizumab clinical trials
Michael H Schiff
1*, Joel M Kremer
2, Angelika Jahreis
3, Emma Vernon
4, John D Isaacs
5 and
Ronald F van Vollenhoven
6
Abstract
Introduction: The efficacy and safety of tocilizumab in patients with rheumatoid arthritis have been evaluated in a
comprehensive phase 3 program. Patients from these randomized trials could receive tocilizumab treatment in
open-label extension trials. Here, the long-term safety profile of tocilizumab, using pooled data from all of these
trials, is reported.
Methods: Cumulative safety data (as of February 6, 2009) from five core phase 3 trials, two ongoing extension
trials, and one clinical pharmacology study were analyzed. Two patient populations were evaluated: an all-control
population (n = 4,199), which included all patients randomly assigned in the placebo-controlled portions of the
five core studies, and an all-exposed population (n = 4,009), which included patients from any of the eight studies
who received at least one dose of tocilizumab.
Results: Total exposure to tocilizumab was 8,580 patient years (PY), and total duration of observation was 9,414 PY.
Overall adverse event (AE) and serious AE (SAE) rates were 278.2/100 PY and 14.4/100 PY, respectively. These
events included serious infections (4.7/100 PY), opportunistic infections (0.23/100 PY), gastrointestinal perforations
(0.28/100 PY), malignancy (1.1/100 PY), myocardial infarction (0.25/100 PY), and stroke (0.19/100 PY). The rates of
SAEs and serious infections were stable over time; no increase with prolonged exposure was noted.
Conclusions: The longer-term safety profile of tocilizumab (mean treatment duration, 2.4 years) is consistent with
that observed in the phase 3 studies (duration up to 1 year).
Introduction
Biologic agents that target tumor necrosis factor (TNF),
B cells, T cells, or, most recently, interleukin-6 (IL-6)
have emerged as effective treatments for patients with
rheumatoid arthritis (RA). As with any new approach,
evaluation of the safety profile associated with a particu-
lar treatment is critical.
Tocilizumab, a humanized monoclonal antibody that
binds to both soluble and membrane-expressed IL-6
receptors, thereby blocking IL-6-mediated proinflamma-
tory signaling, has one of the most comprehensive phase
3 clinical trial programs for biologicals in RA. In combi-
nation with disease-modifying antirheumatic drugs
(DMARDs), tocilizumab improved signs and symptoms
of RA [1-3] and inhibited radiographic progression of
RA [4] in patients with inadequate responses to
DMARDs or TNF inhibitors. Compared with
methotrexate monotherapy, tocilizumab monotherapy
also was significantly more effective in patients who had
not been exposed to methotrexate or for whom metho-
trexate had not previously failed [5]. Overall, the onset
of tocilizumab clinical benefit is rapid, and efficacy is
sustained over time; reduced levels of inflammatory
markers are observed as early as 14 days after the start
of treatment [1-3,5,6].
Although the safety profile of tocilizumab was evalu-
ated in each clinical trial, integrated data across all
phase 3 studies [1-5] provide a more comprehensive pic-
ture of tocilizumab safety. Here we report pooled tocili-
zumab safety data and compare them with those of a
control group from the RA phase 3 studies. Patients
who participated in the randomized, placebo-controlled
trials could continue to receive tocilizumab treatment in
open-label extensions; therefore, this report includes
long-term tocilizumab safety data not previously
reported. We describe the longer-term safety profile of
tocilizumab from these phase 3 studies and open-label
extensions.
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Data sources and patient populations
Included in this analysis are cumulative safety data from
five core phase 3 clinical trials:
tOcilizumab Pivotal Trial in methotrexate Inadequate
respONders (OPTION) [1], Actemra (Roche; Nutley, NJ,
USA) versus Methotrexate double-Blind Investigative
Trial In mONotherapy (AMBITION) [5] (including the
double-blind transition phase), Research on Actemra
Determining efficacy after Anti-TNF failurEs (RADI-
ATE) [2], Tocilizumab in cOmbination With traditional
DMARD therapy (TOWARD) [3], and tociLIzumab
safety and THE prevention of structural joint damage
(LITHE) [4] (including the ongoing open-label extension
phase). Data also are included from the ongoing exten-
sion trials GROWTH95 and GROWTH96 and from a
clinical pharmacology study [7] (Figure 1). The data cut-
off date for inclusion in this analysis was February 6,
2009. Data that were corrected after the cutoff date are
reported as corrected data. Given the relatively similar
designs, populations, and data collection methods of the
studies, individual patient data were pooled rather than
weighted by study in a meta-analysis.
The all-control population included all patients ran-
d o m l ya s s i g n e di nt h ef i v ec o r es t u d i e s .D a t aw e r e
included from double-blind phases of each core study,
from randomization until the first change in treat-
ment regimen (either to rescue therapy with tocilizu-
mab or on entering the extension studies, including
the open-label LITHE extension) or until 2 years of
treatment.
The all-exposed population included all patients who
received tocilizumab treatment (from their first tocilizu-
mab dose (either in a core or an extension study) up to
a cutoff date of February 6, 2009). Mean treatment
duration was 2.4 years, and median treatment duration
was 2.6 years (range, 0.0 to 4.1 years). Patients entered
GROWTH 95 through August 2005 until February 2007
and GROWTH 96 through September 2005 until Febru-
ary 2008; both studies are ongoing. Patients continued
background DMARD therapy unless adjustments or
interruptions were required for safety reasons. Patients
who received placebo during the controlled studies and
who subsequently chose to enter the long-term exten-
sion studies were given tocilizumab 8 mg/kg once every
4 weeks.
Randomized Trials Open-label 
Extension Trialsb
Patients With 1 Dose of TCZc
(Randomized + Open label Extension Trials)
1N  =  2 3
(MTX 8 weeks)
• Weekly MTX + single-dose 
10 mg/kg TCZ  
8 wks
2 N = 673 • MTX 24 wks
Extension Trials (Randomized + Open-label Extension Trials)
2 N   673 
(6-mos MTX free)
MTX
• 8 mg/kg TCZ
24 wks
3 N = 499 
(TNF-IR)
• Placebo
• 4 mg/kg TCZ + MTX
• 8 mg/kg TCZ + MTX
24 wks
8 mg/kg TCZ 
± MTX/DMARDs
5 y n = 2263
• 8 mg/kg TCZ + MTX
4 N = 1220 
(DMARD-IR)
• Placebo
• 8 mg/kg TCZ + DMARDs
24 wks
5 N = 623  • Placebo 24 wks
(DMARD-IR) • 4 mg/kg TCZ + MTX
• 8 mg/kg TCZ + MTX
6 N = 1196
(DMARD-IR)
• Placebo
• 4 mg/kg TCZ + MTX
2 yrs
8 mg/kg TCZ 
+ MTX
5 y n = 597
8 mg/kg TCZ 3-5y n = 1149 (DMARD IR) • 4 mg/kg TCZ + MTX
• 8 mg/kg TCZ + MTX
ALL-CONTROL POPULATION (n = 4199)a
774 patients initially randomized to 4 mg/kg TCZ
8 mg/kg TCZ 
+ MTX
3-5 y n = 1149
ALL-EXPOSED POPULATION (n = 4009)
774 patients initially randomized to 4 mg/kg TCZ
1870 patients initially randomized to 8 mg/kg TCZ
1555 patients initially randomized to 
control (MTX/DMARDs or placebo)
1870 patients initially randomized to 8 mg/kg TCZ
1365 patients initially randomized to 
control (MTX/DMARDs or placebo)
Figure 1 Summary of clinical trials and patients in the all-exposed population.
aDoes not include patients from study 1;
bExtension studies
are ongoing; most patients receive 8 mg/kg TCZ + MTX/DMARDs;
cAll patients who received TCZ treatment; from their first dose (either in a
core or an extension study) up to a cutoff date of February 6, 2009. DMARD-IR, inadequate responder to disease-modifying antirheumatic drugs;
MTX, methotrexate; study 1, clinical pharmacology study; study 2, AMBITION; study 3, RADIATE; study 4, TOWARD; study 5, OPTION, study 6,
LITHE; TCZ, tocilizumab; TNF-IR, inadequate responder to tumor necrosis factor inhibitor.
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Tocilizumab doses could be withheld or reduced on the
occurrence of certain adverse events (AEs), specifically
severe or frequent infections; significant elevations of
alanine aminotransferase (ALT), aspartate aminotrans-
ferase (AST), or bilirubin; or decreases in absolute neu-
trophil count (ANC) or platelet count. In the placebo-
controlled studies, dose modification was limited to
skipping or interrupting an infusion of tocilizumab/pla-
cebo. In the long-term extension studies, a patient’s
tocilizumab dose could be decreased from 8 mg/kg to 4
mg/kg or skipped.
Dose and route of administration of methotrexate or
other nonbiologic DMARDs, nonsteroidal anti-inflam-
matory drugs (NSAIDs), and oral corticosteroids were
maintained in accordance with study entry through the
placebo-controlled period of the trials. However, reduc-
tions in these treatments were allowed as clinically
required for safety reasons.
Safety and laboratory assessments
General safety measures, including AEs, serious AEs
(SAEs), AEs leading to treatment discontinuation, and
deaths were recorded. An AE was defined as any unto-
ward medical occurrence in a patient who had been
administered study treatment; a causal relation with the
treatment was not necessary. An SAE was defined as
any event that fulfilled regulatory seriousness criteria,
including events leading to hospitalization, persistent or
significant disability, medically significant events, or
death. Multiple occurrences of the same AE in indivi-
dual patients were counted once. Events of special inter-
est (that is, serious infections; opportunistic infections,
including tuberculosis (TB); gastrointestinal (GI) per-
forations; malignancies; myocardial infarction, and
stroke; and anaphylactic reactions) are described later.
Infections, opportunistic infections, malignancies, myo-
cardial infarction, and stroke summaries were each
based on a standardized group of preferred terms from
the Medical Dictionary for Regulatory Activities (Med-
DRA); in these summaries, multiple occurrences of the
same AE in individual patients were counted to assess
overall event rates. Neutrophil and platelet counts, hepa-
tic transaminase (ALT and AST) levels, and lipid levels
were monitored by routine laboratory collections at
scheduled visits (see Laboratory assessments later).
Exposure to tocilizumab
The extent of tocilizumab exposure was calculated by
assigning 28 days to each infusion received. Total dura-
tion of observation was defined as the time from the
first tocilizumab dose to the time of the last safety
observation, regardless of whether this observation was
reported within 28 days of the last tocilizumab dose.
Total duration of observation was used as the denomi-
nator for patient-adjusted AE rates.
Laboratory assessments
Fasting lipid levels, including total, low-density lipopro-
tein (LDL) and high-density lipoprotein (HDL) choles-
terol and triglycerides, were measured at baseline; at
weeks 6, 14, and 24; and every 12 weeks thereafter.
ALT, AST, and bilirubin levels were measured at base-
line; at weeks 2, 4, 6, 8, 12, 14, 16, 20, and 24; and every
12 weeks thereafter. Complete blood counts (hemoglo-
bin, hematocrit, red blood cells, white blood cells, and
differential (absolute and percentage) and platelets) were
p e r f o r m e da tb a s e l i n e ;a tw e e k s2 ,4 ,6 ,8 ,1 2 ,1 4 ,a n d
16; and every 4 weeks thereafter in the core studies.
Complete blood counts were performed at baseline; at
weeks 2, 4, 6, 8, and 12; and every 4 weeks thereafter in
the extension studies. Laboratory measurements
occurred before tocilizumab infusions, and investigators
were unaware of test results at the time of infusion.
Depending on the trial, it was either recommended or
mandated that tocilizumab be permanently discontinued
in any patient with the following laboratory values: a
single ALT or AST measurement ≥ 5× the upper limit
of normal (ULN) or two measurements ≥ 3× ULN at
two consecutive study visits, a single total bilirubin level
≥ 2× ULN, or a neutrophil count < 0.5 × 10
9/L. Tocili-
zumab treatment was withheld in any patient with an
ALT or AST level ≥ 3× ULN until the level reached <
3× ULN. For liver enzyme assessments, the controlled,
double-blind population was used because the mono-
therapy groups were specifically separated with regard
to these measures for this population. Data were
included up to only 6 months; patients randomly
assigned to placebo for 8 weeks followed by tocilizumab
for 16 weeks in a substudy of AMBITION were not
included.
Results
Patient populations
The all-control population consisted of all patients ran-
domly assigned in the five core studies; data from the
double-blind periods were collected from randomization
until the first change in treatment regimen or until 2
years of treatment. This population (n = 4,199) included
1,555 patients randomly assigned to the control groups
(placebo ± methotrexate or placebo ± other DMARD
(s)); 774 patients randomly assigned to tocilizumab 4
mg/kg + DMARD; and 1,870 patients randomly assigned
to tocilizumab 8 mg/kg + DMARD. Duration of obser-
vation was 825 patient years (PY) for the control group,
565 PY for the tocilizumab 4 mg/kg + DMARD group,
and 1,194 PY for the tocilizumab 8 mg/kg + DMARD
group.
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data were included from the five core studies for 1,170
patients in the control group (placebo + DMARD(s));
284 patients in the methotrexate monotherapy group;
774 patients in the tocilizumab 4 mg/kg + methotrexate
group; 1,582 patients in the tocilizumab 8 mg/kg +
DMARD group; and 288 patients in the tocilizumab 8
mg/kg monotherapy group.
The all-exposed population included 4,009 patients who
received at least one tocilizumab dose. Within this popula-
tion, most of the tocilizumab exposure was at the 8-mg/kg
dose: duration of tocilizumab exposure was 8,580 PY (817
PY for tocilizumab 4 mg/kg; 7,761 PY for tocilizumab 8
mg/kg; and 2 PY for tocilizumab 10 mg/kg). Total duration
of observation was 9,414 PY, which is used as the denomi-
nator for the patient-adjusted AE rates presented hereafter.
Overall safety
In the all-control population, the overall rate of AEs was
339.0/100 PY in the control group, 358.0/100 PY in the
tocilizumab 4-mg/kg group, and 381.6/100 PY in the
tocilizumab 8-mg/kg group. Rates of infection were
105.8/100 PY in the control group, 115.7/100 PY in the
tocilizumab 4-mg/kg group, and 112.7/100 PY in the
tocilizumab 8-mg/kg group The rate of SAEs was
similar across the three treatment groups (control, 14.4/
100 PY; tocilizumab 4 mg/kg, 13.6/100 PY; tocilizumab
8 mg/kg, 14.5/100 PY). SAEs reported at a rate of 0.3 or
more per 100 PY in any group within the all-control
population are shown in Table 1. Infections were the
most frequently reported type of AE and SAE.
In the all-exposed population, the AE rate was 278.2/
100 PY. The most frequently reported types of AEs
were infections (81.0/100 PY), usually upper respira-
tory tract infections and nasopharyngitis. GI disorders
(usually diarrhea and nausea) occurred at a rate of
36.4/100 PY. The rate of AEs leading to discontinua-
tion was 5.8/100 PY. Rates of AEs, AEs related to
treatment, and AEs leading to discontinuation were
highest during the first 6 months of tocilizumab treat-
ment and decreased thereafter (Table 2). The rate of
SAEs, which did not increase with prolonged exposure,
was 14.4/100 PY.
The rate of death in the all-control population was 0.73/
100 PY in the control group, 0/100 PY in the tocilizumab
4-mg/kg group, and 0.75/100 PY in the tocilizumab 8-mg/
kg group. In the all-exposed population, the rate of death
was 0.53/100 PY (50 cases). Most frequently reported
causes of death were cardiac events (13 cases), serious
infections (12 cases), and malignancies (eight cases).
Table 1 Serious adverse events reported at a rate of ≥ 0.3 per 100 patient-years in any group (all-control population)
All-control population
n = 4,199
Control
n = 1,555
Tocilizumab
4 mg/kg + DMARDs
n = 774
Tocilizumab
8 mg/kg + DMARDs
n = 1,870
Rate per 100 PY (number of events)
Pneumonia 0.6 (5) 0.7 (4) 0.9 (11)
Cellulitis 0.2 (2) – 0.9 (11)
Gastroenteritis 0.2 (2) 0.5 (3) 0.1 (1)
Urinary tract infection 0.5 (4) 0.2 (1) 0.1 (1)
Sepsis 0.1 (1) 0.4 (2) 0.2 (2)
Herpes zoster 0.1 (1) – 0.3 (4)
Fall 0.1 (1) – 0.3 (4)
Pulmonary embolism 0.2 (2) – 0.3 (3)
Basal cell carcinoma 0.1 (1) 0.4 (2) 0.1 (1)
Spinal compression fracture 0.1 (1) – 0.3 (3)
Coronary artery disease – 0.2 (1) 0.3 (3)
Back pain 0.1 (1) – 0.3 (3)
Rheumatoid arthritis 0.4 (3) ––
Gastroenteritis viral 0.1 (1) 0.4 (2) –
Prostate cancer 0.1 (1) 0.4 (2) –
Neutropenia – 0.4 (2) 0.1 (1)
Syncope – 0.4 (2) –
Tendon rupture – 0.4 (2) –
Interstitial lung disease – 0.4 (2) –
Anaphylactic reaction – 0.4 (2) –
DMARD, disease-modifying antirheumatic drug; PY, patient-years.
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treatment discontinuation or dose reduction
In the all-control population, the rate of AEs leading to
treatment discontinuation was 6.9/100 PY in the control
group and 10.1/100 PY and 10.2/100 PY in the tocilizu-
mab 4-mg/kg and 8-mg/kg groups, respectively. Infec-
tions were the most common AEs leading to
discontinuation in the control group (1.3/100 PY), and
liver function test abnormalities were the most common
AEs leading to discontinuation in the tocilizumab
groups (2.5/100 PY, 4-mg/kg group; 2.8/100 PY, 8-mg/
kg group). The most common AEs leading to dose mod-
ification or interruption were infections (12.2/100 PY
(control group), 15.8/100 PY (tocilizumab 4-mg/kg
group), and 15.2/100 PY (tocilizumab 8-mg/kg group)).
In the all-exposed population, the most frequently
reported AEs leading to treatment discontinuation were
investigations (1.3/100 PY, primarily hepatic transami-
nase elevations) and infections (1.1/100 PY, primarily
pneumonia and cellulitis). Fifty-six patients withdrew
because of malignant neoplasms (including one patient
with nonmelanoma skin cancer), and 43 patients with-
drew because of GI disorders. The most common AEs
leading to reductions in tocilizumab dose from 8 to 4
mg/kg were laboratory abnormalities (primarily
increased aminotransferases). Of the 257 AEs (in 217
patients) managed by dose reduction, 247 (96%) resulted
in continuation of tocilizumab therapy.
Serious infections
In the all-control population, rates of serious infections
were 3.5/100 PY for the control group, 3.5/100 PY for
the tocilizumab 4-mg/kg group, and 4.9/100 PY for the
tocilizumab 8-mg/kg group. Higher rates of serious
infection, regardless of whether infections were in the
control or the tocilizumab groups, were associated
with increased age, body mass index ≥ 30, previous use
of a TNF inhibitor, and history of chronic (obstructive
or restrictive) pulmonary disease or diabetes (for con-
trol and tocilizumab 8 mg/kg) (Table 3). The rate of
s e r i o u sp n e u m o n i aw a sh i g h e ri np a t i e n t sw i t h( 4 . 9 /
100 PY) than without (0.8/100 PY) chronic pulmonary
disease.
In the all-exposed population, the rate of serious
infections was 4.7/100 PY, and the most frequent events
were pneumonia (1.0/100 PY), gastroenteritis, and urin-
ary tract infections. The rate of serious infections
remained relatively stable with continued tocilizumab
treatment (Figure 2). However, rates increased with age:
2.9/100 PY for patients younger than 50, 5.1/100 PY for
patients 50 to 64, and to 8.1/100 PY for patients 65 and
older.
Opportunistic infections
Overall, 22 opportunistic infections (0.23/100 PY), 14 of
which were serious, were reported in 20 patients in the
all-exposed population. The types of opportunistic infec-
tions included TB (eight cases), candidiasis (systemic,
esophageal, GI, osteomyelitis; six cases), fungal infec-
tions (microorganism not specified; three cases), other
mycobacterial infections (Mycobacterium avium and
nonspecified; one case each), and Pneumocystis jiroveci
pneumonia and cryptococcal pneumonia (one case
each). All opportunistic infections occurred in patients
treated with tocilizumab 8 mg/kg, except for P. jiroveci
pneumonia, which occurred in a patient treated with
tocilizumab 4 mg/kg. No opportunistic infections were
reported in the control group.
Table 2 Rates of adverse events by duration of observation in the all-exposed population
All-exposed population
n = 4,009
Overall ≤ 6
months
7-12 months 13-18 months > 18 months
Total duration, PY 9,414 1,805 1,664 1,542 4,404
AEs, rate/100 PY
Any
a 278.2 441.1 340.4 284.7 245.5
Severe
a, b 18.0 24.0 20.7 17.3 15.3
Treatment related
a, c 112.8 214.7 141.0 106.4 85.2
Led to withdrawal
a 5.8 11.5 6.7 4.9 3.5
Led to dose modification/
interruption
a
36.6 41.3 40.2 37.3 37.8
SAEs, rate/100 PY
Any
a 14.4 15.9 15.1 13.9 14.0
Treatment related
c 5.0 6.0 5.1 4.0 4.9
AE, adverse event; PY, patient-years; SAE, serious AE.
aMultiple occurrences of the same AE in one individual are counted once in each period.
bIntensity of AEs
graded by the investigator as mild, moderate, or severe.
cRelated AEs are those considered by the investigator to be remotely, possibly, or probably related to
study drug.
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Investigators were instructed to screen for TB according
to local guidelines for RA patients starting biologic ther-
apy. Chest radiographs were obtained for all patients at
the screening visit. In the all-exposed population, eight
cases of infections with M. tuberculosis (see previous
paragraph) were reported in seven patients; for one
patient, tuberculosis pleurisy and TB were reported dur-
ing the same episode. None of the patients with avail-
able data reported a relevant medical history, history of
TB, or previous known exposure to TB. All patients
were treated with concomitant DMARDs. Pulmonary
TB was reported in four patients, tuberculosis pleurisy
in three, and tuberculosis (not otherwise specified) in
one. The patients with pulmonary TB were from Thai-
land, Spain, South Africa, and Peru, and had symptoms
of productive cough, hemoptysis, pleuritic pain, and fati-
gue, or chest radiograph findings suggestive of TB.
Tuberculosis pleurisy was described in three patients
from Singapore, Brazil, and Peru. M. tuberculosis was
confirmed by polymerase chain reaction in a patient
who had a foot abscess and negative findings on the
tuberculin test in Mexico.
Gastrointestinal perforations
Hospital, surgical, and discharge summaries from cases
of GI perforation were medically reviewed. In the all-
control population, diverticular perforation occurred in
one patient in the tocilizumab 4-mg/kg group (0.2/100
PY) and in two patients in the tocilizumab 8-mg/kg
group (0.2/100 PY). In the all-exposed population, 26
cases (0.28/100 PY) were identified as perforations,
Table 3 Rates of serious infections (overall and by baseline characteristics) in the all-control population
Exposure, PY Control
n = 1,555
Exposure, PY Tocilizumab
4 mg/kg + DMARDs
n = 774
Exposure, PY Tocilizumab
8 mg/kg + DMARDs
n = 1,870
Rate/100 PY
a (number of events
b)
Overall 824.6 3.5 (29) 564.6 3.5 (20) 1,194.1 4.9 (59)
Rate/100 PY
a (95% CI
a), (number of events
b)
Age, years
< 50 340.2 1.5 (0.5, 3.4), (5) 244.2 1.6 (0.5, 4.2), (4) 431.3 1.9 (0.8, 3.7), (8)
≥ 50-64 354.2 3.7 (2.0, 6.3), (13) 229.9 3.5 (1.5, 6.9), (8) 572.8 5.9 (4.1, 8.3), (34)
≥ 65 130.1 8.5 (4.2, 15.1), (10) 90.6 8.8 (3.8, 17.4), (8) 189.9 9.0 (5.2, 14.3), (17)
BMI,
c kg/m
2
< 18.5 29.2 – 9.6 – 31.3 16.0 (5.2, 37.3), (5)
18.5-24.9 282.1 2.8 (1.2, 5.6), (7) 209.4 3.8 (1.7, 7.5), (8) 414.4 2.7 (1.3, 4.8), (11)
25-29.9 275.6 3.6 (1.7, 6.7), (10) 187.2 3.2 (1.2, 7.0), (6) 412.5 5.3 (3.3, 8.1), (22)
≥ 30 234.2 4.7 (2.3, 8.4), (11) 154.7 3.9 (1.4, 8.4), (6) 327.8 6.1 (3.7, 9.4), (20)
Background corticosteroid use
Yes 570.5 3.3 (2.0, 5.2), (18) 426.6 4.7 (2.9, 7.2), (20) 788.3 5.3 (3.8, 7.2), (42)
No 254.0 3.9 (1.9, 7.2), (10) 138.0 – 405.8 4.2 (2.4, 6.7), (17)
Previous TNF-a inhibitor therapy
Yes 134.6 6.7 (3.1, 12.7), (9) 114.4 5.3 (1.9, 11.4), (6) 200.1 8.5 (5.0, 13.6), (17)
No 690.0 2.9 (1.8, 4.5), (19) 450.2 3.1 (1.7, 5.2), (14) 994.0 4.2 (3.1, 5.7), (42)
Chronic pulmonary disease
Yes 38.9 10.3 (2.8, 26.3), (3) 28.4 10.6 (2.2, 30.8), (3) 54.1 7.4 (2.0, 18.9), (4)
No 785.6 3.2 (2.1, 4.7), (25) 536.2 3.2 (1.9, 5.1), (17) 1,140.0 4.8 (3.6, 6.3), (55)
Serious infections
Yes – 10.3 (2.8, 26.3), (3) – 10.6 (2.2, 30.8), (3) – 7.4 (2.0, 18.9), (4)
No – 3.2 (2.1, 4.7), (25) – 3.2 (1.9, 5.1), (17) – 4.8 (3.6, 6.3), (55)
Serious pneumonia
Yes – 7.7 (1.6, 22.5) – 3.5 (0.1, 19.6) – 5.6 (1.1, 16.2)
No – 0.4 (0.1, 1.1) – 0.9 (0.3, 2.2) – 0.9 (0.4, 1.6)
Diabetes
Yes 66.6 7.5 (2.4, 17.5), (5) 54.1 1.9 (0.1, 10.3), (1) 99.4 12.1 (6.2, 21.1), (12)
No 758.0 3.2 (2.0, 4.7), (23) 510.5 3.7 (2.2, 5.8), (19) 1,094.7 4.3 (3.2, 5.7), (47)
BMI, body mass index; CI, confidence interval; DMARD, disease-modifying antirheumatic drug; PY, patient-years; TNF, tumor necrosis factor.
aMultiple occurrences of the same adverse event (AE) in one individual are counted.
bMultiple occurrences of the same AE in one individual are counted only
once.
cTwenty-two patients did not have BMI values.
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appendicitis (two cases), diverticulitis (three cases), fistula
(one case), and GI perforations (16 cases, including 11
diverticular perforations). Eighteen of these events
occurred in the colon, of which 16 occurred in patients
with underlying diverticulitis. Most (65%) patients with
GI perforations were women, with a mean age of 58.5
years at trial enrollment. Three patients with GI perfora-
tions died–one of postprocedural esophageal perforation,
one of perforation associated with an upper GI bleed,
and one of complications of diverticular perforation.
Malignancies
Overall rates of malignancy (including nonmelanoma
skin cancer) in the all-control population were 0.7/100
PY, 1.4/100 PY, and 0.7/100 PY in the control, tocilizu-
mab 4-mg/kg and tocilizumab 8-mg/kg groups, respec-
tively. In the all-exposed population, the overall rate of
malignancy was 1.1/100 PY. Rates were 0.6/100 PY for
solid cancer, 0.4/100 PY for nonmelanoma skin cancers,
< 0.1/100 PY for hematologic/lymphatic cancers, and <
0.1/100 PY for other cancers. Overall rates of malig-
nancy remained stable over time, and no increase was
found with prolonged exposure. The overall rate of
malignancy of 1.1/100 PY in this analysis of the all-
exposure population was comparable to the rate of 1.3/
100 PY observed in a contemporary large United States
cohort of RA patients (41,912 PY) in which 62% of
patients were treated with TNF inhibitors [8]. The stan-
dardized incidence ratio for all cancer types (excluding
nonmelanoma skin cancers) compared with the US Sur-
veillance and Epidemiology End Results database was
0.80 (95% CI, 0.78, 0.82) in the current analysis, indicat-
ing no statistically significant difference compared with
the general population.
Myocardial infarction and stroke
The overall number of cardiovascular (CV) events that
occurred during the placebo-controlled period of the
studies was low (Table 4). In the all-control population,
the myocardial infarction rate was 0.49/100 PY in the
control group, 0.18/100 PY in the tocilizumab 4-mg/kg
group, and 0.17/100 PY in the tocilizumab 8-mg/kg
group. The rate of strokes was 0.24/100 PY in the con-
trol group, 0/100 PY in the tocilizumab 4-mg/kg group,
and 0.33/100 PY in the tocilizumab 8-mg/kg group
(Table 4). In the all-exposed population, the myocardial
infarction rate was 0.25/100 PY (95% CI, 0.16, 0.38), and
the rate of stroke was 0.19/100 PY (95% CI, 0.11, 0.30)
at 9,414 PY of exposure. Rates were assessed by 6-
month intervals, and no apparent trend toward an
increase was noted over time. Two CV events occurred
within 10 days of starting tocilizumab dosing: acute cor-
onary syndrome in a patient with high-grade, three-ves-
sel disease, which necessitated a four-vessel coronary
artery bypass on day 13; and carotid artery stenosis in a
patient with 90% occlusion of the right carotid artery, as
assessed by ultrasound on day 18.
Anaphylactic reactions
In the all-control population, three anaphylactic reac-
tions were reported in the tocilizumab 4-mg/kg group
(0.5/100 PY), and one was reported in the tocilizumab
8-mg/kg group (0.1/100 PY). In the all-exposed popula-
tion, eight clinically significant anaphylactic reactions,
including the four cases from the all-control population,
were reported. Symptoms included urticaria, nausea,
vomiting, hypotension, hypotensive shock, and bronch-
ospasm. All eight patients with anaphylaxis were
required to discontinue tocilizumab treatment. Five
events occurred in patients treated with tocilizumab 4
mg/kg, and three events occurred in patients treated
with tocilizumab 8 mg/kg. Seven events occurred during
the first four infusions of tocilizumab. One late event
occurred after completion of the 16th infusion, 15 hours
after tocilizumab infusion.
Laboratory parameters
Neutrophil count
Blood samples were obtained immediately before each
tocilizumab infusion. In the all-control population,
decreases from baseline to week 2 in mean neutrophil
count were noted in all three groups: 5.91 × 10
9/L to
5.87 × 10
9/L in the control group, 5.96 to 4.38 × 10
9/L
in the tocilizumab 4-mg/kg group, and 5.82 to 3.68 ×
10
9/L in the tocilizumab 8-mg/kg group. At week 4,
mean neutrophil counts increased to 5.89 × 10
9/L, 5.70
×1 0
9/L, and 4.31 × 10
9/L, respectively; corresponding
values at week 24 were 5.46 × 10
9/L, 5.10 × 10
9/L, and
3.83 × 10
9/L.
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Figure 2 Rates of serious infections (95% confidence intervals)
in the all-exposed population by 6-month periods. PY, patient-
years. Multiple occurrences of the same adverse event in a patient
in a 6-month period were counted as individual events.
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Page 7 of 13Mean neutrophil count in the all-exposed population
was 5.82 × 10
9/L at baseline. From the first postdose
assessment (week 2), mean neutrophil count remained
relatively stable over time: for example, values at weeks
2, 4, and 24 were 3.85, 4.61, and 4.07 × 10
9/L, respec-
tively. Common toxicity criteria (CTC) grade 3 neutro-
penia (ANC 0.5 to < 1.0 × 10
9/L) was reported in 4.1%
of patients (165/3,992). CTC grade 4 (ANC < 0.5 × 10
9/
L) neutropenia while receiving tocilizumab was reported
in 0.6% of patients (24/3,992); 16 of the 24 patients with
CTC grade 4 neutropenia discontinued tocilizumab
treatment. For 15 patients, further neutrophil data were
available, and neutrophil counts returned to normal
levels in all but one patient. This patient was enrolled in
the clinical trial despite neutropenia at baseline. Of the
24 patients who had CTC grade 4 neutropenia while
receiving tocilizumab, eight continued treatment. All
eight experienced improvements in neutropenia–at the
time of database cutoff, neutrophil counts recovered to
within normal range in five patients, and neutropenia
recovered to CTC grade 2 in three patients. No patient
with CTC grade 4 neutropenia experienced a temporally
associated serious infection. A single patient with CTC
grade 3 neutropenia reported a serious infection
(empyema) that occurred shortly after CTC grade 3
neutropenia became evident.
Platelet count
In the all-control population, mean platelet count was
unchanged from baseline to week 2 in the control group
(339 × 10
9/L). However, decreases in mean platelet
count occurred in the tocilizumab groups (337 × 10
9/L
at baseline to 259 × 10
9/L at week 2 in the 4-mg/kg
group; 334 × 10
9/L at baseline to 249 × 10
9/L at week 2
in the 8-mg/kg group). After week 2, mean platelet
counts remained relatively unchanged. In the all-
exposed population, 32 patients had thrombocytopenia
(either ≥ 25 to < 50 × 10
9/L platelets (grade 3, 13
patients) or < 25 × 10
9/L platelets (grade 4, 19
patients)). One serious bleeding event (hemorrhagic sto-
matitis) occurred in a patient with CTC grade 4 throm-
bocytopenia. The 8-mg/kg dose was maintained, and the
event resolved without sequelae.
Hemoglobin
In the all-control population, the mean hemoglobin level
was 13.5 g/dl at baseline in all three groups. At weeks 2
and 6, levels were 13.3 g/dl in controls; 14.1 g/dl and
14.2 g/dl, respectively, in the tocilizumab 4-mg/kg
group; and 14.1 g/dl and 14.4 g/dl, respectively, in the
tocilizumab 8-mg/kg group. Mean baseline hemoglobin
level in the all-exposed population was 13.4 g/dl. Subse-
quently, the level increased to 14.0 g/dl (week 2), 14.3
g/dl (week 6), and 14.8 g/dl (week 104). Approximately
34% of patients who previously had inadequate
r e s p o n s e st oD M A R D sh a dh e m o g l o b i nv a l u e sb e l o w
the lower limit of normal at baseline. After treatment
with tocilizumab, the greatest improvement in hemoglo-
bin levels was observed in these patients, whose baseline
hemoglobin values were below the lower limit of nor-
mal. In this subset, mean hemoglobin concentrations
increased in the tocilizumab-treated group to within the
lower limit of normal, whereas mean levels in the con-
trol group remained below the lower limit of normal.
Assessment of lipids
Fasting lipid levels were assessed during the tocilizumab
development program. In the all-control population,
mean LDL levels in the control, tocilizumab 4-mg/kg,
and tocilizumab 8-mg/kg groups were 114 mg/dl (n =
1,404), 113 mg/dl (n =6 9 0 ) ,a n d1 1 3m g / d l( n =1 , 6 8 6 ) ,
respectively, at baseline, and 117 mg/dl (n =9 3 9 ) ,1 2 7
mg/dl (n = 536), and 136 mg/dl (n = 1,419), respectively,
at week 24. LDL cholesterol changes from < 130 mg/dl
at baseline to ≥ 1 3 0m g / d la tl a s to b s e r v a t i o nw e r e
assessed in patients not receiving lipid-lowering agents;
14.2% (123/867) in the control group, 25.1% (106/423)
in the tocilizumab 4-mg/kg group, and 33.2% (349/
1,052) in the tocilizumab 8-mg/kg group experienced
these elevations in LDL cholesterol levels.
In the all-exposed population, mean total cholesterol,
LDL, HDL, and triglyceride levels increased from base-
line to the first assessment after tocilizumab infusion at
week 6 and remained at week 6 levels with continued
tocilizumab treatment (Table 5). At baseline, 70.8% of
patients had LDL levels < 130 mg/dl. This proportion
decreased to 49.9% at week 24 and remained relatively
Table 4 Rates of myocardial infarction and stroke in the all-control population
All-control population
n = 4,199
Control
n = 1,555
Tocilizumab
4 mg/kg + DMARDs
n = 774
Tocilizumab
8 mg/kg + DMARDs
n = 1,870
Rate/100 PY (95% CI), (number of events)
Myocardial infarction 0.49 (0.13, 1.24), (4) 0.18 (0.00, 0.99), (1) 0.17 (0.02, 0.61), (2)
Stroke 0.24 (0.03, 0.88), (2) 0.0 0.33 (0.09, 0.86), (4)
CI, confidence interval; DMARD, disease-modifying antirheumatic drug; PY, patient-years. Multiple occurrences of the same adverse event in individual patients
were counted.
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Page 8 of 13constant throughout the trial (for example, 48.2% at
week 104 and 45.9% at week 200). Overall, 456 patients
in the all-exposed population started treatment with
lipid-lowering medications at some point during the
study. Assessment of the exact effect and the time
course of the effect of lipid-lowering medications is diffi-
cult because of the wide range of times at which
patients started taking these medications in the trials.
Furthermore, initiation and dosing of lipid-lowering
therapy were not standardized but were based on the
discretion of the treating physician. However, after an
initial increase in mean LDL level, a decrease to a level
similar to that at baseline was observed in this sub-
group: baseline (135 mg/dl), week 6 (167 mg/dl), week
52 (152 mg/dl), and week 104 (139 mg/dl) (Table 6).
Transaminase elevations
Liver enzyme elevations were assessed in the controlled,
double-blind periods of the original studies. Patients
treated with monotherapy had less-pronounced liver
enzyme elevations than did patients treated with combi-
nation therapy; 32% and 3.7% of patients treated with
methotrexate monotherapy; 19.1% and 1.1% of patients
treated with non-methotrexate DMARD monotherapy;
and 33.8% and 1.9% of patients treated with tocilizumab
8-mg/kg monotherapy each had at least a single increase
in ALT level from normal at baseline to > 1 to 3× ULN
or > 3× ULN, respectively, as the highest value during
the double-blind period. Further, 42.8% and 5.0% of
patients treated with tocilizumab 4 mg/kg + DMARD,
and 45.9% and 5.7% of patients treated with tocilizumab
8 mg/kg + DMARD, each had at least a single elevation
in ALT level from normal at baseline to > 1 to 3× ULN
or > 3× ULN, respectively, as their highest value during
the double-blind period (Table 6). Changes in AST
values were similar (Table 6).
In the all-exposed population, 9.5% and 3.1% of
patients treated with tocilizumab had increases in ALT
or AST levels from normal at baseline to > 3× ULN at
any time up to the time of database lock. Overall, 1.6% of
patients had tocilizumab dose reductions from 8 mg/kg
to 4 mg/kg; 0.4% of patients had DMARD dose reduc-
tions; 9.3% of patients temporarily interrupted tocilizu-
mab dosing; and 1% of patients had interrupted DMARD
and tocilizumab dosing because of liver enzyme eleva-
tions > 3× ULN. Most patients continued therapy after
dose reduction; 2.3% of patients withdrew from treat-
ment because of elevated liver function tests (Table 6). In
the all-control population, mean total bilirubin levels at
baseline were 5 to 6 μmol/L (0.30 to 0.35 mg/dl) in all
groups. Mean increases to week 4 in total and indirect
bilirubin levels were ≤ 2 μmol/L (0.12 mg/dl) in all
groups. These values remained stable during the long-
term extension studies, and no clinically relevant effect
was noted on direct bilirubin, albumin, alkaline phospha-
tase, or any other liver function parameter. Further, no
evidence was seen of clinically significant hepatitis or
drug-induced liver injury associated with transaminase
elevations in patients treated with tocilizumab.
Liver biopsies were recommended but not required for
patients whose liver-enzyme elevations did not normal-
ize within 6 months of discontinuation from the study
and were obtained at the investigators’ discretion. Of
the 11 liver biopsy samples evaluated by an independent
hepatic pathology expert, steatohepatitis was present in
nine patients. Seven of the nine patients had ≥ 1 clinical
risk factor (excluding methotrexate use) for nonalcoholic
steatohepatitis, including obesity, diabetes, and hyperlipi-
demia. The two patients with normal liver biopsy sam-
ples had no risk factors for liver disease and had no
history of previous liver disease.
Table 5 Lipid parameters
a in the all-exposed population (n = 4,009)
Parameter (mg/dl) Baseline Week 6 Week 52
b Week 104
Mean total cholesterol 196.2
(n = 3,714)
227.6
(n = 3,279)
222.9
(n = 1,312)
224.1
(n = 828)
Mean LDL cholesterol 114.2
(n = 3,633)
135.5
(n = 3,149)
133.5
(n = 1,274)
134.3
(n = 805)
Mean HDL cholesterol 56.9
(n = 3,656)
60.8
(n = 3,249)
60.0
(n = 1,301)
60.0
(n = 826)
Mean triglycerides 127.6
(n = 3,715)
160.4
(n = 3,280)
148.8
(n = 1,312)
148.8
(n = 828)
Patients starting lipid-lowering medication
at any time up to week 104 during the trial (n = 456)
Mean total cholesterol 223.3
(n = 415)
267.4
(n = 375)
247.7
(n = 154)
236.1
(n = 109)
Mean LDL cholesterol 135.1
(n = 402)
167.6
(n = 338)
152.9
(n = 142)
138.9
(n = 97)
HDL, high-density lipoprotein; LDL, low-density lipoprotein.
aFasted samples only.
bPatient numbers declined after week 6 because patients’ 12-week fasted lipid-
analysis schedules might not have coincided with week 52, depending on when they started tocilizumab treatment (that is, some patients had their fasted lipid
analysis at week 48 or week 56).
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The safety profile of tocilizumab was extensively evalu-
ated in five trials in patients with RA, and the pooled
safety data from these phase 3 trials and their long-term
extensions are described herein. The longer-term safety
profile of tocilizumab (mean treatment duration, 2.4
years) is consistent with that observed in the phase 3
studies (treatment duration, up to 1 year). Notably, no
increases in serious or treatment-related AEs were
observed with prolonged exposure to tocilizumab. Rates
of SAEs, including deaths, were similar to those
observed in RA clinical trials for other biologic therapies
[9], although direct comparison of rates may be inap-
propriate because of differences in study designs and
populations. Further, data from this pooled safety report
are consistent overall with the postmarketing trials and
experience with tocilizumab.
Patients with RA are approximately twice as likely as the
general population to acquire infections or serious infec-
tions [10,11]. This increased risk for infection is attributed
to intrinsic disease-related factors (for example, immunolo-
gic abnormalities [12]), age, extra-articular manifestations,
leukopenia, comorbidities, and treatment-related factors
(for example, use of corticosteroids) [13]. In the current
analysis, rates of serious infection in the control and tocili-
zumab-treated groups were higher in patients with preex-
isting pulmonary disease, diabetes, older age, or higher
body mass index and in those concomitantly treated with
steroids or previously treated with a TNF inhibitor.
Overall, infections were the most common AEs and
SAEs reported during the studies included in this
analysis. Compared with the control group, rates of
infections were higher in the tocilizumab 8-mg/kg group
than in the tocilizumab 4-mg/kg group. Eight cases of
infections with TB were reported in seven patients, all
of whom received tocilizumab 8 mg/kg. The most com-
mon serious infections involved the skin (cellulitis) and
lung (pneumonia). Importantly, rates of serious infection
did not increase with prolonged use of tocilizumab, and
serious infections occurred at rates similar to those
reported for RA patients treated with TNF inhibitors or
other biologic agents [14,15]. Patients with RA treated
with any biologic treatment, including tocilizumab,
should be closely monitored for the development of
infections, and–according to American College of Rheu-
matology Recommendations for Use of Nonbiologic and
Biologic DMARDs [16]–treatment should not be started
in a patient with an active infection. Recommendations
also include routine TB screening for patients being
considered for biologic therapy and clinical vigilance
during long-term treatment.
In the current analysis, 26 cases (0.28/100 PY) of GI
perforation, including three fatal perforations, were
observed during treatment with tocilizumab. According
to the results of a retrospective, claims-based study that
evaluated 40,841 RA patients treated with biologic
agents, methotrexate, oral glucocorticoids, and NSAIDs,
GI perforation is an uncommon (0.11 hospitalizations
with GI perforation per 100 PY) SAE among RA
patients [17]. Oral glucocorticosteroid use and preexist-
ing diverticulitis were independently associated risk fac-
tors for GI perforation. Overall, 70% of RA patients with
Table 6 Changes in ALT/AST values from normal at baseline to highest value in the all-control and in the all-exposed
population
Controlled, double-blind study population All-exposed
population
Tocilizumab 8 mg/kg
monotherapy,
%( n)
n = 288
Methotrexate
(control),
%( n)
n = 284
Tocilizumab 4 mg/kg
+ DMARDs,
%( n)
n = 774
Tocilizumab 8 mg/kg
+ DMARDs,
%( n)
n = 1,582
DMARD
monotherapy,
%( n)
n = 1,170
Tocilizumab,
% (n/n)
n = 4,009
c
ALT,
a n = normal
at baseline
n = 269 n = 269 n = 706 n = 1,465 n = 1,080
> 1-3× ULN
> 3-5× ULN
> 5× ULN
33.8 (91)
1.1 (3)
0.7 (2)
32.0 (86)
2.6 (7)
1.1 (3)
42.8 (302)
4.0 (28)
1.0 (7)
45.9 (672)
4.3 (63)
1.4 (20)
19.1 (206)
0.8 (9)
0.3 (3)
57.3 (2,112/
3,696)
7.2 (267/3,696)
2.2 (83/3,696)
AST,
a n = normal
at baseline
n = 283 n = 269 n = 743 n = 1,502 n = 1,123
> 1-3× ULN
> 3-5× ULN
> 5× ULN
20.8 (59)
0.4 (1)
0.7 (2)
24.9 (67)
1.1 (3)
0.4 (1)
32.4 (241)
0.9 (7)
–
38.8 (583)
1.5 (23)
0.2 (3)
14.5 (163)
0.3 (3)
0.1 (1)
51.4 (1,961/
3,818)
2.6 (98/3,818)
0.6 (22/3,818)
Dose held
b 8.0 (23) 9.9 (28) 2.5 (19) 2.5 (39) 0.7 (8) 10.3 (413/4,009)
Discontinued 0.3 (1)
b 1.4 (4)
b 1.3 (10)
b 1.3 (21)
b 0.2 (2)
b 2.3 (91/4,002)
ALT, alanine aminotransferase; AST, aspartate aminotransferase; DMARD, disease-modifying antirheumatic drug; ULN, upper limit of normal.
aPercentages are
based on number of patients with normal ALT (or AST) at baseline.
bPercentages are based on total treatment-group sample size.
cExcluding patients with
missing values.
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risk factors. Therefore, RA patients who are treated with
glucocorticoids or who have previously experienced
diverticulitis should be considered at higher risk for GI
perforation. Tocilizumab-treated patients with new-
onset abdominal symptoms should be evaluated
promptly for the early identification of GI perforation.
In this integrated summary of safety, eight clinically
significant anaphylactic reactions to tocilizumab infu-
sions were reported. Most of these events occurred with
the 4-mg/kg tocilizumab dose and early during treat-
ment. During tocilizumab infusion, treatment should be
stopped immediately and appropriate medical manage-
ment should be started if an anaphylactic or other ser-
ious hypersensitivity reaction occurs. Tocilizumab
should be permanently discontinued in patients who
experience these reactions.
Increases in hepatic transaminase (ALT and AST)
levels were observed in some patients in the phase 3
trials [1-5]. These increases were generally mild and
reversible. Increases in ALT or AST to either > 1 to 3×
ULN or > 3× ULN in patients treated with tocilizumab
were less common with tocilizumab monotherapy.
Importantly, liver enzyme elevations were not associated
with clinically apparent drug-induced liver injury.
Because of the potential for increases in hepatic transa-
minase levels, these laboratory values should be moni-
tored before and during tocilizumab therapy, and dose
adjustments–including interruption or permanent dis-
continuation of tocilizumab or concomitant DMARD
(particularly methotrexate)–should be considered if
appropriate.
Finally, RA has been associated with an increased risk
for CV disease and CV-related deaths [18-21], despite
the paradoxically low lipid levels (total cholesterol, HDL,
and LDL) seen with active disease and inflammation.
Although the pathogenic mechanisms involved in accel-
erated CV disease in RA patients are complex and mul-
tifactorial, the underlying systemic inflammation has
been postulated to promote accelerated atherosclerosis.
This concept is supported by the fact that inflammatory
markers such as CRP have been shown to be indepen-
dent predictors of CV events in the general population
[22,23], and the reduction of hsCRP by rosuvastatin in
the JUPITER study reduced the incidence of major CV
events [24]. Reducing the inflammatory burden of RA
by lowering CRP and IL-6 levels may, therefore, reduce
CV risk in RA patients [25-27]. In this pooled data set,
rates of myocardial infarction and stroke were similar to
those reported in epidemiologic studies of RA patients
[18,28,29]. Aggressive prevention and treatment of tradi-
tional and nontraditional CV risk factors, including con-
trol of inflammation, immunologic disturbances, and
metabolic changes, are of paramount importance in RA
patients. Like patients without RA, patients with RA–
particularly those actively treated–should be monitored
and managed according to clinical guidelines (for exam-
ple, the National Cholesterol Education Program). Lipid
parameters should be assessed 4 to 8 weeks after the
start of RA treatment and at 6-month intervals there-
after; the addition of lipid-lowering agents in patients
with persistently elevated lipid levels should be
considered.
In summary, this report provides an account of the
safety profile of tocilizumab from phase 3 clinical trials
and their respective open-label extensions. Results
demonstrate that the longer-term safety profile of tocili-
zumab is consistent with that observed in phase 3 stu-
dies, with no increases in serious or treatment-related
AEs on prolonged exposure to tocilizumab. Similar trial
designs and data collection allowed the pooling of indi-
vidual patient data and resulted in a very large RA ran-
domized controlled trial data set with extensive long-
term exposure. However, as with any randomized con-
trolled trial, patients were assessed for strict entry cri-
teria, and the observations were made in a clinical trial
setting with rigorous patient monitoring and laboratory
testing protocols. Several of the laboratory abnormalities
described in this report, such as cytopenias and liver
function abnormalities, did not lead to clinically signifi-
cant sequelae, possibly because of the close supervision
of the clinical trial setting. It would, therefore, be pru-
dent for clinicians to use similarly careful patient moni-
toring strategies for tocilizumab-treated patients in the
clinical practice setting. Of note, however, the results of
this integrated safety analysis are consistent overall with
data from postmarketing surveillance to date.
Conclusions
Results from the current analysis confirm that the
longer-term safety profile of tocilizumab in RA patients
is consistent with that previously described [1-5]. No
new safety findings emerged in this large, pooled dataset
with an extended treatment and observation period.
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